Status:
COMPLETED
Effect of Cholecalciferol Supplementation on Disease Activity and Quality of Life of Systemic Lupus Erythematosus Patients .
Lead Sponsor:
Dr Cipto Mangunkusumo General Hospital
Conditions:
Lupus Erythematosus, Systemic
Cholecalciferol Supplementation
Eligibility:
FEMALE
18-60 years
Phase:
PHASE3
Brief Summary
Increase in the prevalence and survival rates has led to the assessment of disease activity and quality of life of SLE patients as targets in treatment. Cholecalciferol supplementation was considered ...
Eligibility Criteria
Inclusion
- Women subjects aged 18-60 years old with hypovitaminosis D
Exclusion
- declining consent to participate, late stage chronic kidney disease (staged 4-5), decompensated liver cirrhosis, consumption of glucocorticoids (equivalent to prednisone 20 mg/day) in the past 30 days, pregnant or lactating, patients with acute infection, hypercalcemic patients, anticonvulsant consumption.
Key Trial Info
Start Date :
October 3 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 11 2022
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05326841
Start Date
October 3 2021
End Date
January 11 2022
Last Update
April 14 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rscm Divisi Alergi Imunologi
Jakarta Pusat, Dki Jakarta, Indonesia, 10430